Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025;25(1):63-74.
doi: 10.2174/0118715206331206240828111126.

Evaluation of Novel Diaza Cage Compounds as MRP Modulators in Cancer Cells

Henry Döring  1 , David Kreutzer  1 , Jannis von Veh  1 , Christoph A Ritter  2 , Andreas Hilgeroth  1
Affiliations

Evaluation of Novel Diaza Cage Compounds as MRP Modulators in Cancer Cells

Henry Döring et al. Anticancer Agents Med Chem. 2025.

Abstract

Aim: Novel MRP modulators are needed to combat MRP-mediated multidrug resistance (MDR) in cancer cells.

Background: Anticancer drug resistance is the main problem in cancer therapy. Causative multidrug efflux pumps are attractive target structures for the development of inhibitors of their activity.

Objective: We synthesized novel cage dimeric 1,4-dihydropyridines to evaluate them as MRP modulators in cancer cells targeting MRP1, MRP2, and MRP4.

Methods: Cage compounds were synthesized by solution dimerization of monomeric 1,4-dihydropyridines and a final functionalization reaction. The MRP modulation was determined in cellular efflux assays by the use of the flow cytometry technique as well as cellular fluorescent measurements with each fluorescent substrate of the efflux pumps.

Results: Difluoro phenyl and methoxy or dimethoxy benzyl substitutions were most favourable for the MRP1 and MRP2 inhibition, whereas monofluor phenyl and dimethoxy benzyl substitutions were most favourable for the MRP4 inhibition.

Conclusion: Effective inhibitors were identified that were demonstrated to restore the respective cancer cell line sensitivity for the anticancer drug as a proof-of-concept that encourages further preclinical studies.

Keywords: Drug development; MDR modulating activity; MRP4; cellular efflux assays.; small-molecule inhibitors; substituent effects.

PubMed Disclaimer

References

    1. Cancer. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer2024
    1. Yan L.; Rosen N.; Arteaga C.; Targeted cancer therapies. Chin J Cancer 2011,30(1),1-4 - DOI - PubMed
    1. Sarkar N.; Singh A.; Kumar P.; Kaushik M.; Protein kinases: Role of their dysregulation in carcinogenesis, identification and inhibition. Drug Res (Stuttg) 2023,73(4),189-199 - DOI - PubMed
    1. Li J.; Gong C.; Zhou H.; Liu J.; Xia X.; Ha W.; Jiang Y.; Liu Q.; Xiong H.; Kinase inhibitors and kinase-targeted cancer therapies: recent advances and future perspectives. Int J Mol Sci 2024,25(10),5489 - DOI - PubMed
    1. Protein kinase inhibitors. Available from: https://brimr.org/protein-kinase-inhibitors/2024

MeSH terms

Substances

LinkOut - more resources